期刊文献+

肾脏移植患者血浆霉酚酸浓度的高效液相色谱法测定

Determination of Bioactive Metabolite Mycophenolic Acid of Mycophenolate Mofetil in Human Plasma by HPLC
下载PDF
导出
摘要 目的:建立快速测定肾脏移植血浆中麦考吗乙酯(Myeophenolate mofetil,MMF)活性代谢物霉酚酸(Mycophenolie acid,MPA)的高效液相色谱测定方法。方法:色谱条件为分析柱:Hypersil ODS2(4.6mm×200mm,5μm);流动相:A相:25%乙腈+75%0.02mol/L KH2PO4缓冲液(pH3.0),B相:70%乙腈+30%0.02mol/L K2HPO4缓冲液(pH6.5);梯度洗脱程序:0—14.5min为分析梯度,霉酚酸在8.7min出峰,继续用100%B流动相清洗4min。流速:1.0ml/min;检测波长254nm;柱温30℃;进样量100μl。9例肾脏移植患者13服MMF1.5g,不同时间采血,测定血浆中霉酚酸的浓度并计算药动学参数。结果:本方法线性范围为0.10—27mg/L时,峰面积与浓度呈良好的线性关系(r=0.9998),最低检出浓度为4μg/L,方法回收率分别为97.20%、98.73%和98.61%,日内精密度和日间精密度分别为3.5%、1.7%、0.6%和5.5%、3.0%、1.1%。药代动力学参数表明霉酚酸的平均血药浓度-时间曲线符合一室开放模型,tmax,ccma和AUC0-12h分别为0.94h、11.30mg/L和30.35mg·h·L^-1。结论:用高效液相色谱法梯度洗脱测定肾脏移植患者霉酚酸血药浓度,操作简便,结果准确。 Objective:To establish a quick HPLC method for determination of bioactive metabolite Mycophenolic acid(MPA) of M ycophenolate mofetil (MMF) in human plasma. Methods :The chromatographic conditions include Hypersil ODS2 (4.6 mm × 200 mm,5 μm) ; mobile phase: gradient eluation of A[25% acetonitrile + 75% 0.02 mol/L KH2PO4 buffer (pH3.0) ] -B [ 70% aectonitrile + 30% 0. 02 mol/L K2HPO4 buffer( pH 6.5) ] ,flow rate at 1.0 ml/min, wavelength 254 rim,column temperature was 30℃ and the dosage of MPA was 100 μl. The pharmacokinetic parameters of MPA taken by 9 patients showed standard curve in plasma. Results:The standard curve was linear( r= 0. 9998) with the range of 0. 10 - 27 mg/L for MPA. The limit of detection in plasma was 4 μg/L. The average recovery was 97.20% , 98.73% and 98.61% , respectively. The intra day precision and inter day precision were 3.5%, 1.7% , 0.6% and 5.5% ,3.0%, 1.1% , respectively. The results showed that the pharmacokinetic of MPA was in accordance with the one compartment open model, tmax, cmax and AUC0 -12h was 0.94 h, 11.30 mg/L and 30.35 mg·h·L^-1, respectively. Conclusion : The resolution, linearity, precision and average recovery of MPA can all meet the requirement of quantitative determination. The method is rapid,accurate and reliable.
机构地区 北京军区总医院
出处 《华北国防医药》 2006年第6期388-390,共3页 Medical Journal of Beijing Military Region
关键词 肾移植 霉酚酸 麦考酚吗乙酯 色谱法 高效液相 Kidney transplant Mycophelie acid Mycophenolate mofctil Chromatography, high performance liquid
  • 相关文献

参考文献6

  • 1刘晓琰,施安国,费艳秋,王平全.免疫抑制剂研究进展[J].中国新药杂志,2001,10(1):17-20. 被引量:2
  • 2Sanquer S,Breil M,Baron C,et al.Trough blood concentrations in long-term treatment with mycophenolate mofeti[J].Lancet,1998,351:1557-1561. 被引量:1
  • 3郭宏波,张玉海.霉酚酸酯(MMF)在肾移植中的应用[J].中国新药杂志,1998,7(6):444-446. 被引量:5
  • 4Shipkaova M,Niedmann PD,Armstrong VM,et al.Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure[J].Clin Chem,1998,44:1481-1488. 被引量:1
  • 5Jones CE,Taylor PJ,Johnson AG,et al.High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma[J].J Chromatogr B Biomed Sci Appl,1998,708:229-234. 被引量:1
  • 6Na-Bangchang K,Supasyndh O,Supaporn T,et al.Simple and sensitive high-performance liquid chromatographic[J].J Chromatogr B Biomed Sci Appl,2000,738:169-173. 被引量:1

二级参考文献15

  • 1[1]Opelz G. Influence of treatment with cyclosporine,azathio prine and steroi ds on chronic allograft failure. The Collaborative Transplant Study[J].Kidn ey Int,1995,52(Suppl)∶S89-S92. 被引量:1
  • 2[2]Nicholls AJ.Opportunities for therapeutic drug monitoring of myco phenola te mofetil dose in renal transplantation suggested by the pharmacokinetic/pharma codynamic relationship for mycophenolic acid and suppression of rejection[J]. Clin Biochem,1998,31(5)∶329-333. 被引量:1
  • 3[3]Meiser BM,Pfeiffer M,Jagiello-Kraatz M,et al. Mycophenolate mofetil dose adjustment based on trough levels improves outcome after heart transplantio n[J].J Heart Lung Transplant,1998,17(1)∶85-90. 被引量:1
  • 4[4]Shaw LM,Nicholls A,Hale M,et al. Therapeutic monitoring of my cophenol ic acid: A consensus panel report[J].Clin Biochem,1998,31(5)∶317-322. 被引量:1
  • 5[5]Zanker B,Schneeberger H,Rothenpieler U, et al. Mycophenolate mofetil -based,cyclosporin-free induction and maintenance immunosuppression[J].Tr ansplantation,1998,66(1)∶44-49. 被引量:1
  • 6[6]Przepiorka D,Nash RA,Wingard JR,et al. Relationship of tacrol imus who le blood levels to efficacy and safety outcomes after unrelated donor marrow tra nsplantation[J].Biol Blood Marrow Transplant,1999,5(2)∶94-99. 被引量:1
  • 7[7]McMaster P,Mirza DF,Ismail T,et al. Therapeutic drug monitori ng of ta crolimus in clinical transplantation[J].Ther Drug Monit, 1995,17(6)∶602 -605. 被引量:1
  • 8[8]Zucker K,Tsaroucha A,Olson L,et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophen olic acid glucuronidation[J].Ther Drug Monit,1999,21(1)∶35-43. 被引量:1
  • 9[9]Meiser BM,Pfeiffer M,Schmidt D,et al. Combination therapy wit h tacrol imus and mycophenolate mofetil following cardiac transplantation:importance of m ycophenolic acid therapeutic drug monitoring[J].J Heart Lung Transplant,1 999,18(2)∶143-149. 被引量:1
  • 10[10]Hedayat S,Kershner RP,Su G. Relationship of whole blood FK506 concentrat ions to rejection and toxicity in liver and kidney transplants[J].J Biophar m Stat,1996,6(4)∶411-424. 被引量:1

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部